跳至主要内容
临床试验/JPRN-UMIN000028101
JPRN-UMIN000028101尚未招募2 期

Multicenter phase II study of neoadjuvant chemotherapy of gemcitabine+nab-paclitaxel therapy for patients with resectable pancreatic cancer. - Multicenter phase II study of neoadjuvant GEM+nab-PTX for resectable pancreatic cancer.

Division of Hepato-biliary-pancreatic Surgery Department of Surgery, Kobe University Graduate School of Medicine0 个研究点目标入组 45 人开始时间: 2017年8月15日最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
45

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. History of gemcitabine, nab-paclitaxel 2. Ongoing active other malignancy 3. Allergic to gemcitabine and nab- 4. Computed tomography contrast media allergy 5. poor control of diarrhea 6. Intestinal pneumonia 7. Moderate amount of ascites or pleural effusion 8. Active infection 9. Poor control of diabetes mellitus 10. Serious comorbid conditions 11.Myocardial infarction within last 6 months 12. Systemic steroid therapy 13. Serious psychiatric diseases 14. Planning a baby or pregnancy 15. Planning a baby 16. Judged unable to guarantee safety

研究者

发起方
Division of Hepato-biliary-pancreatic Surgery Department of Surgery, Kobe University Graduate School of Medicine

相似试验